Ironwood Pharmaceuticals/$IRWD

1D1W1MYTD1Y5YMAX

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
Ticker
$IRWD
Sector
Health
Primary listing
NASDAQ
Employees
100
Headquarters
Boston, United States
Website
ironwoodpharma.com

IRWD Metrics

BasicAdvanced
$674M
5.17
$0.79
0.21
-

What the Analysts think about IRWD

Analyst ratings (Buy, Hold, Sell) for Ironwood Pharmaceuticals stock.
Analyst projections of the future price of Ironwood Pharmaceuticals stock.

Bulls say / Bears say

GAAP net income jumped 117% year-over-year to $51.29 million in Q2 FY26, while revenue rose 33% to $113.04 million, driven by robust LINZESS performance (Reuters)
The company raised its full-year FY26 revenue guidance to $460 million–$485 million and adjusted EBITDA guidance to above $310 million on August 6, underscoring management’s confidence in sustained LINZESS cash flows (Reuters)
Ironwood initiated its confirmatory Phase 3 STARS-2 trial of apraglutide in June and is now actively recruiting patients, marking a key advance in its rare disease pipeline (Reuters)
Q2 FY26 revenue of $113.04 million fell short of the $114.8 million IBES consensus estimate, raising concerns about the sustainability of LINZESS-driven top-line growth (Reuters)
Shareholders approved a 10 million-share increase to the Amended and Restated 2019 Equity Incentive Plan at the June 16, 2026 annual meeting, potentially diluting existing shareholders’ ownership (SEC)
Interim CFO Ronald Silver sold 127,890 shares on July 7, 2026 for approximately $578,063.80, which may signal insider caution about the near-term outlook (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.

IRWD Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

IRWD Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

IRWD News

AllArticlesVideos

Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference

Business Wire2 weeks ago

Ironwood Pharmaceuticals Q2 Earnings Call Highlights

MarketBeat1 month ago

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

Business Wire1 month ago

Funds containing IRWD

AllUSDGBPEUR
Funds
Fund name
Fund size
$IRWD weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.05%
iShares Nasdaq US Biotechnology£BTEK
£865M0.05%
Xtrackers S&P 500 Swap£XSPX
£3.1B0.04%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.02%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.